 Connection
Andrey Soares to Aged
This is a "connection" page, showing publications Andrey Soares has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.241 |
|
|
|
-
Santoni M, Büttner T, Rescigno P, Fiala O, Cavasin N, Basso U, Taha T, Massari F, Myint ZW, Formisano L, Galli L, Scagliarini S, Matrana MR, Facchini G, Bamias A, Messina C, Zacchi F, Manneh RK, Roviello G, Santini D, Poprach A, Navratil J, Uher M, Calabrò F, Pierce E, Berardi R, Aurilio G, Zakopoulou R, Rizzo A, Ansari J, Rizzo M, Bisonni R, Mollica V, Incorvaia L, Spinelli G, Jiang XY, Chandler RA, Grillone F, Morelli F, Buti S, Maluf FC, Marques Monteiro FS, Battelli N, Porta C, Caffo O, Soares A. Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study. Eur Urol Oncol. 2025 Apr; 8(2):444-451.
Score: 0.057
-
Rizzo A, Zayed A, Vitale E, Buti S, Takeshita H, Crabb S, Roviello G, Seront E, Tapia JC, Scagliarini S, Popovic L, Kopp RM, Abahssain H, Rizzo M, Monteiro FSM, Massafra R, Brunetti O, Santini D, Ürün Y, Montironi R, Mollica V, Massari F, Soares A, Santoni M. Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset. Clin Exp Metastasis. 2025 Sep 06; 42(5):52.
Score: 0.015
-
Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M. Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study. Eur Urol Focus. 2025 Sep; 11(5):736-746.
Score: 0.015
-
Rizzo M, Soares A, Gupta S, Calabrò F, Takeshita H, Bourlon MT, Park SH, Giannatempo P, Myint ZW, Büttner T, Grande E, Fiala O, Santini D, Bamias A, Zakopoulou R, Buti S, Kanesvaran R, Rescigno P, Molina-Cerrillo J, Epstein I, Marques Monteiro FS, Massari F, Porta C, Bellmunt J, Santoni M. Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study. JCO Glob Oncol. 2025 Jul; 11:e2400564.
Score: 0.015
-
Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M. Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study. Cancer Immunol Immunother. 2025 May 09; 74(7):196.
Score: 0.015
-
Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, Popovic L, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, Santoni M. Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience. Cancer Med. 2025 Feb; 14(4):e70479.
Score: 0.014
-
Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, Monteiro FSM, Cattrini C, Landmesser J, Messina C, Zgura A, Rebuzzi SE, Soares A, Carrozza F, Ansari J, Grillone F, Küronya Z, Incorvaia L, Bhuva D, Ortega C, Nasso C, Kanesvaran R, Zampiva I, Porta C, Buti S, Santoni M. First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study. Cancer Immunol Immunother. 2025 Jan 03; 74(2):65.
Score: 0.014
-
Villa CH, Biondich P, Draper NL, Dores GM, Storch E, Chada K, Wong HL, Whitaker B, Obidi J, Vossoughi S, Soares A, Schilling LM, Natarajan K, Goodman M, Purkayastha S, Zucker R, Falconer T, Williams N, Reich C, Anderson S, Shoaibi A. Patterns of platelet use evaluated in EHR networks of the Biologics Effectiveness and Safety Initiative, 2012-2018. Transfusion. 2025 Feb; 65(2):267-276.
Score: 0.014
-
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study. Target Oncol. 2024 Nov; 19(6):905-915.
Score: 0.014
-
Santini D, Li H, Roviello G, Park SH, Grande E, Kucharz J, Basso U, Fiala O, Monteiro FSM, Poprach A, Buti S, Molina-Cerrillo J, Catalano M, Buchler T, Seront E, Ansari J, Myint ZW, Ghosn M, Calabrò F, Kopp RM, Bhuva D, Bourlon MT, Roberto M, Di Civita MA, Mollica V, Marchetti A, Soares A, Battelli N, Ricci M, Kanesvaran R, Bamias A, Porta C, Massari F, Santoni M. Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1). Target Oncol. 2024 Nov; 19(6):893-903.
Score: 0.014
-
Rizzo M, Soares A, Grande E, Bamias A, Kopp RM, Lenci E, Buttner T, Salah S, Grillone F, de Carvalho IT, Tapia JC, Gucciardino C, Pinto A, Mennitto A, Abahssain H, Rescigno P, Myint Z, Takeshita H, Spinelli GP, Popovic L, Vitale MG, Fiala O, Giannatempo P, Zakopoulou R, Carrozza F, Massari F, Monteiro FSM, Pace MP, Giannini M, Roviello G, Porta C, Battelli N, Kanesvaran R, Santoni M. Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study. Sci Rep. 2024 08 27; 14(1):19802.
Score: 0.014
-
Incorvaia L, Monteiro FSM, Massari F, Park SH, Roviello G, Fiala O, Myint ZW, Kucharz J, Molina-Cerrillo J, Santini D, Buttner T, Poprach A, Kopecky J, Zeppellini A, Pichler M, Buchler T, Pichler R, Facchini G, Fay AP, Soares A, Manneh R, Iezzi L, Kuronya Z, Russo A, Bourlon MT, Bhuva D, Ansari J, Kanesvaran R, Grande E, Buti S, Santoni M. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. Cancer Immunol Immunother. 2024 Jun 04; 73(8):142.
Score: 0.014
-
Obidi J, Sridhar G, Dores GM, Whitaker B, Villa CH, Storch E, Chada K, Schilling LM, Natarajan K, Biondich P, Soares A, Spotnitz M, Falconer T, Purkayastha S, Draper NL, Wong HL, Stagg M, Reich C, Anderson S, Shoaibi A. Patterns of red blood cell utilization: Harnessing electronic health records data from the Information Standard for Blood and Transplant (ISBT) 128 system within the Biologics Effectiveness and Safety (BEST) initiative. Transfusion. 2024 06; 64(6):998-1007.
Score: 0.014
-
Alper BS, Dehnbostel J, Afzal M, Subbian V, Soares A, Kunnamo I, Shahin K, McClure RC. Making science computable: Developing code systems for statistics, study design, and risk of bias. J Biomed Inform. 2021 03; 115:103685.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|